Healthcare · Drug Manufacturers - General
Price
$0.09
Market Cap
$183.8M
Employees
34,100
Beta
-0.54
Avg Volume
39,355
CEO
Christopher S. Boerner
Business Description
Bristol Myers Squibb Company (BMS) operates as a biopharmaceutical enterprise, managing the entire lifecycle of its therapeutic products, from initial discovery and development to manufacturing, marketing, and distribution. Its diverse portfolio includes conventional small molecule drugs, advanced biologics (which are derived from biological processes), and specialized chimeric antigen receptor (CAR-T) cell therapies. The company was established in August 1933 and maintains its corporate headquarters in Princeton, New Jersey.
Business History
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
0.02
Stock Price: $0.09
EPS (Diluted): 5.51
EPS (Diluted): 5.51
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
7.63
Stock Price: $0.09
Total Equity: $6.16B
Shares: 733,800,000
Total Equity: $6.16B
Shares: 733,800,000
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
10.16
Market Cap: $183.79M
Total Debt: $20.27B
Cash: $4.23B
EBITDA: $6.21B
Total Debt: $20.27B
Cash: $4.23B
EBITDA: $6.21B
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$63.1B
Market Cap: $183.79M
Total Debt: $20.27B
Cash: $4.23B
Total Debt: $20.27B
Cash: $4.23B
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
96.2%
Gross Profit: $14.69B
Revenue: $15.28B
Revenue: $15.28B
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
34.0%
Operating Income: $5.19B
Revenue: $15.28B
Revenue: $15.28B
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
26.5%
Net Income: $4.05B
Revenue: $15.28B
Revenue: $15.28B
ROE (Profit from shareholder equity)
CALCNet Income / Total Equity
65.7%
Net Income: $4.05B
Total Equity: $6.16B
Total Equity: $6.16B
ROIC (Profit from all invested capital)
CALCNOPAT / Invested Capital
19.6%
Operating Income: $5.19B
Tax Rate: 16.3%
Equity: $6.16B
Total Debt: $20.27B
Cash: $4.23B
Tax Rate: 16.3%
Equity: $6.16B
Total Debt: $20.27B
Cash: $4.23B
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
2.23
Current Assets: $9.07B
Current Liabilities: $4.06B
Current Liabilities: $4.06B
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
3.29
Short-Term Debt: $501.00M
Long-Term Debt: $19.77B
Total Debt: $20.27B
Total Equity: $6.16B
Long-Term Debt: $19.77B
Total Debt: $20.27B
Total Equity: $6.16B
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$20.82
Revenue: $15.28B
Shares: 733,800,000
Shares: 733,800,000
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$8.40
Total Equity: $6.16B
Shares: 733,800,000
Shares: 733,800,000
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$6.60
Operating CF: $5.17B
CapEx: -$330.00M
Shares: 733,800,000
CapEx: -$330.00M
Shares: 733,800,000
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $0.09
Stock Price: $0.09
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: $4.05B
Net Income: $4.05B
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares CELG-RI against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 26, 2026 4:31pm (16h ago)| Metric | 2014 | 2015 | 2016 | 2017 | 2018 |
|---|---|---|---|---|---|
| Revenue | $7.7B | $9.3B | $11.2B | $13.0B | $15.3B |
| Cost of Revenue | $385.9M | $420.1M | $438.0M | $461.0M | $587.0M |
| Gross Profit | $7.3B | $8.8B | $10.8B | $12.5B | $14.7B |
| Operating Expenses | $4.5B | $6.0B | $7.1B | $8.9B | $8.9B |
| Operating Income | $2.5B | $2.3B | $3.2B | $4.7B | $5.2B |
| Net Income | $2.0B | $1.6B | $2.0B | $2.9B | $4.0B |
| EBITDA | $2.9B | $2.7B | $3.4B | $5.3B | $6.2B |
| EPS | $2.49 | $2.02 | $2.57 | $3.77 | $5.51 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 26, 2026 4:31pm (16h ago)| Metric | 2014 | 2015 | 2016 | 2017 | 2018 |
|---|---|---|---|---|---|
| Cash & Equivalents | $4.1B | $4.9B | $6.2B | $7.0B | $4.2B |
| Total Current Assets | $9.7B | $9.4B | $10.9B | $14.9B | $9.1B |
| Total Assets | $17.3B | $27.1B | $28.1B | $30.1B | $35.5B |
| Current Liabilities | $2.1B | $2.0B | $3.0B | $3.0B | $4.1B |
| Long-Term Debt | $6.3B | $14.3B | $13.8B | $15.8B | $19.8B |
| Total Liabilities | $10.8B | $21.1B | $21.5B | $23.2B | $29.3B |
| Total Equity | $6.5B | $5.9B | $6.6B | $6.9B | $6.2B |
| Retained Earnings | $6.5B | $8.1B | $10.1B | $13.1B | $17.6B |
Cash Flow (Annual)
Last updated: Jun 26, 2026 4:31pm (16h ago)| Metric | 2014 | 2015 | 2016 | 2017 | 2018 |
|---|---|---|---|---|---|
| Operating Cash Flow | $2.8B | $2.5B | $4.0B | $5.2B | $5.2B |
| Capital Expenditure | -$150.3M | -$286.3M | -$236.2M | -$279.0M | -$330.0M |
| Free Cash Flow | $2.7B | $2.2B | $3.7B | $5.0B | $4.8B |
| Acquisitions (net) | -$710.0M | -$7.7B | $0 | $0 | -$8.6B |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | -$3.0B | -$3.3B | -$2.2B | -$3.8B | -$6.1B |
| Net Change in Cash | $887.6M | $758.7M | $1.3B | $843.0M | -$2.8B |
Analyst Estimates (Annual)
Last updated: Jun 26, 2026 4:31pm (16h ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$46.3B $46.3B – $46.3B
|
$41.0B $41.0B – $41.0B
|
$37.4B $37.4B – $37.4B
|
$36.7B $36.7B – $36.7B
|
| EBITDA |
$16.2B $16.2B – $16.2B
|
$14.3B $14.3B – $14.3B
|
$13.1B $13.1B – $13.1B
|
$12.8B $12.8B – $12.8B
|
| Net Income |
$12.5B $12.5B – $12.5B
|
$11.0B $11.0B – $11.0B
|
$9.9B $9.9B – $9.9B
|
$9.7B $9.7B – $9.7B
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 26, 2026 4:31pm (16h ago)| Metric | 2015 | 2016 | 2017 | 2018 |
|---|---|---|---|---|
| Revenue Growth | +20.7% | +21.3% | +15.8% | +17.5% |
| Gross Profit Growth | +21.3% | +22.1% | +16.2% | +17.2% |
| Operating Income Growth | -10.5% | +40.5% | +48.6% | +10.3% |
| Net Income Growth | -19.9% | +24.8% | +47.1% | +37.6% |
| EBITDA Growth | -4.7% | +23.1% | +57.1% | +17.0% |
Dividend History (Last 20)
Last updated: Jun 26, 2026 4:31pm (16h ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2022-03-03 | $0.10 | 2022-03-06 | 2022-03-07 | |
| 2021-03-04 | $0.14 | 2021-03-05 | 2021-03-08 | |
| 2020-03-18 | $0.15 | 2020-03-19 | 2020-03-20 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for CELG-RI — it's generated by the pipeline (
market-narrative step).
No community reviews yet for CELG-RI.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30